SCH351591, a novel phosphodiesterase-4 inhibitor under investigation as a potential therapeutic for asthma and chronic obstructive pulmonary disease (COPD), was evaluated in a 3-month rising-dose study in Cynomolgus monkeys. Four groups, containing four monkeys/sex, received vehicle control or rising doses up to 12, 24, or 48 mg/kg of SCH351591 daily. Although initial exposure produced clinical signs of emesis, reduced food intake, and reduced body weight, tachyphylaxis to the emesis allowed dose escalation up to 48 mg/kg/day. Two monkeys died and 3 were sacrificed in moribund condition over the course of the study. Early mortality, involving monkeys dosed with 12 or 24 mg/kg, was attributed to sepsis (2 monkeys) or colon inflammation (3 monkeys). Leukocyte function assays on low- and mid-dose group survivors revealed an inhibition of T lymphocyte proliferation for 12 mg/kg group males and 24 mg/kg group monkeys of both sexes. Necropsy findings, unassociated with early mortality, included reduced size and weight of the thymus, depletion of body fat, red discoloration of the gastric mucosa, and perivascular hemorrhage of the stomach and heart. Stomach and heart gross findings were present in the high-dose group only. Histopathologic lesions, in addition to those attributed to concurrent bacterial infection, included thymic atrophy, serous atrophy of fat, myocardial degeneration and acute to chronic inflammation of small to medium-sized arteries in various organs and tissues including the heart, kidneys, stomach, salivary glands, pancreas, esophagus, gallbladder, and mesentery. The findings of this study demonstrate the potential of a PDE4 inhibitor to alter immunologic response as well as to produce arteriopathy in nonhuman primates.
Albassam, M.A., Lillie, L.E., and Smith, G.S. (1993). Asymptomatic polyarteritis in a Cynomolgus monkey . Lab Anim Sci43, 628—9.
2.
Albassam, M.A., Smith, G.S., and Macallum, G.E. (1998). Arteriopathy induced by an adenosine agonist-antihypertensive in monkeys. Tox Pathol26, 375—80.
3.
Aoki, M., Fukunaga, M., Sugimoto, T., Hirano, Y., Kobayashi, M., Honda, K., and Yamada, T. (2001). Studies on mechanisms of low emetogenicity of YM976, a novel phosphodiesterase type 4 inhibitor. J Pharmacol Exp Ther298, 1142—9.
4.
Barnette, M.S., Grous, M., Cieslinski, L.B., Burman, M., Christensen, S.B., and Torphy, T.J. (1995). Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site. J Pharmacol Exp Ther273, 1396—402.
5.
Billah, M., Cooper, N., Minnicozzi, M., Warneck, J., Wang, P., Hey, J.A., Kreutner, W., Rizzo, C.A., Smith, S.R., Young, S., Chapman, R.W., Dyke, H., Shih, N.Y., Piwinski, J.J., Cuss, F.M., Montana, J., Ganguly, A.K., and Egan, R.W. (2002). Pharmacology of N-(3,5-Dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-(trifluoromethyl)-5-quinoline carboxamide (SCH 351591), a novel, orally active phosphodiesterase 4 inhibitor . J Pharmacol Exp Ther302, 127—38.
6.
Bishop, S.P. (1989). Animal models of vasculitis. Toxicol Pathol17, 109—17.
7.
Bober, L.A., Grace, M.J., Pugliese-Sivo, C., Rojas-Triana, A., Waters, T., Sullivan, L.M., and Narula, S.K. (1995). The effect of GM-CSF and G-CSF on human neutrophil function. Immunopharmacol29, 111—9.
8.
Boichot, E., Wallace, J.L., Germain, N., Corbel, M., Lugnier, C., Lagente, V., and Bourguignon, J.J. (2000). Anti-inflammatory activities of a new series of selective phosphodiesterase 4 inhibitors derived from 9-benzyladenine . J Pharmacol Exp Ther292, 647—53.
9.
Boor, P.J., Gotlieb, A.I., Joseph, E.C., Kerns, W.D., Roth, R.A., and Tomaszewski, K.E. (1995). Contemporary issues in toxicology: Chemicalinduced vasculature injury. Toxicol and Appl Pharmacol132, 177—95.
10.
Burnouf, C., Pruniaux, M.P., and Szilagyi, C.M. (1998). Chapter 10: Phosphodiesterase 4 inhibitors. Ann Rep Med Chem33, 91—109.
11.
Campillo, N., and Paez, J. (2001). Novel bronchodilators in the treatment of asthma and COPD. Expert Opin Ther Patents12, 53—63.
12.
Clemo, F.A., Evering, W.E., Snyder, P.W., and Albassam, M.A. (2003). Differentiating spontaneous from drug-induced vascular injury in the dogTox Pathol31(Suppl.), 25—31.
13.
Cortijo, J., Bou, J., Beleta, J., Cardelus, I., Llenas, J., Morcillo, E., and Gristwood, R.W. (1993). Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus. Br J Pharmacol108, 562—8.
14.
de Boer, J., Philpott, A.J., van Amsterdam, R.G., Shahid, M., Zaagsma, J., and Nicholson, C.D. (1992). Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: Biochemical and pharmacological analysis using selective inhibitors . Br J Pharmacol106, 1028—34.
15.
Dogterom, P., and Zbinden, G. (1992). Cardiotoxicity of vasodilators and positive inotropic/vasodilating drugs in dogs: An overview. Crit Rev Toxicol22, 203—41.
Essayan, D.M., Huang, S.K., Kagey-Sobotka, A., and Lichtenstein, L.M. (1995). Effects of nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors on antigen-induced cytokine gene expression in peripheral blood mononuclear cells. Am J Respir Cell Mol Biol13, 692— 702.
18.
Essayan, D.M., Huang, S.K., Kagey-Sobotka, A., and Lichtenstein, L.M. (1997). Differential efficacy of lymphocyte- and monocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene-expression. J Allergy Clin Immunol99, 28—37.
19.
Essayan, D.M., Huang, S.K., Undem, B.J., Kagey-Sobotka, A., and Lichtenstein, L.M. (1994). Modulation of antigen- and mitogen-induced proliferative responses of peripheral blood mononuclear cells by nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J Immunol153, 3408—13.
20.
Feigl, D., Feigl, A., and Edwards, J.E. (1986). Mycotic aneurysms of the aortic root: A pathologic study of 20 cases. Chest90, 553—7.
21.
Gantner, F., Gotz, C., Gekeler, V., Schudt, C., Wendel, A., and Hatzelmann, A. (1998). Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation. Br J Pharmacol123, 1031—8.
22.
Gibaldi, M., and Perrier, D. (1982). In Pharmacokinetics, 2nd edition pp. 409— 17. Marcel Dekker, Inc., New York.
23.
Giembycz, M.A. (2000). Phosphodiesterase 4 inhibitors and the treatment of asthma: Where are we now and where do we go from here? Drugs59, 193—212.
24.
Giembycz, M.A., Corrigan, C.J., Seybold, J., Newton, R., and Barnes, P.J. (1996). Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br J Pharmacol118, 1945—58.
25.
Hanton, G., Le Net, J.L., and Abbott, D. (2000a). Cardiovascular toxicity of UK-57,831, a PDE III inhibitor, in rats. Internat J Toxicol 19(6), Abstracts for the 21st Annual Meeting of the American College of Toxicology, November 12—15, 2000, San Diego, CA. p. 28.
26.
Hanton, G., Le Net, J.L., and Abbott, D. (2000b). Cardiovascular toxicity of UK-61,260, a PDE III inhibitor, in dogs Internat J Toxicol 19(6), Abstracts for the 21st Annual Meeting of the American College of Toxicology, November 12—15, 2000, San Diego, CA. p. 28.
27.
Hanton, G., Le Net, J.L., and Ruty, B. (1995). Characterization of the arteritis induced by infusion of rats with UK-61,260, an inodilator, for 24 h. Arch Toxicol69, 698—704.
28.
Harleman, J.H., Joseph, E.C., Eden, R.J., Walker, T.F., Major, I.R., and Lamb, M.S. (1986). Cardiotoxicity of a new inotrope/vasodilator drug (SK&F 94120) in the dog. Arch Toxicol59, 51—5.
29.
Heaslip, R.J., and Evans, D.Y. (1995). Emetic, central nervous system, and pulmonary activities of rolipram in the dog. Eur J Pharmacol286, 281— 90.
30.
Howell, R.E., Muehsam, W.T., and Kinnier, W.J. (1990). Mechanism for the emetic side effect of xanthine bronchodilators. Life Sci46, 563—8.
31.
Huang, Z., Ducharme, Y., Macdonald, D., and Robichaud, A. (2001). The next generation of PDE4 inhibitors. Curr Opin Chem Biol5, 432—8.
32.
Isaacs, K.R., Joseph, E.C., and Betton, G.R. (1989). Coronary vascular lesions in dogs treated with phosphodiesterase III inhibitors. Toxicol Pathol17, 153—63.
33.
Jones, T.R., McAuliffe, M., McFarlane, C.S., Piechuta, H., Macdonald, D., and Rodger, I.W. (1997). Effects of a selective phosphodiesterase IV inhibitor (CDP-840) in a leukotriene-dependent non-human primate model of allergic asthma . Can J Physiol Pharmacol76, 210—7.
34.
Joseph, E.C., Jones, H.B., and Kerns, W.D. (1996a). Characterization of coronary arterial lesions in the dog following administration of SK&F 95654, a phosphodiesterase III inhibitor. Toxicol Pathol24, 429—35.
35.
Joseph, E.C., Rees, J.A., and Dayan, A.D. (1996b). Mesenteric arteriopathy in the rat induced by phosphodiesterase III inhibitors: An investigation of morphological, ultrastructural, and hemodynamic changes. Toxicol Pathol24, 436—50.
36.
Kammer, G.M. (1988). The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol Today9, 222—9.
37.
Kerns, W.D., and Joseph, E.C. (1991). Drug-induced lesions of the coronary artery, dog . In Cardiovascular and Musculoskeletal Systems (T. C. Jones, U. Mohr , and R. D. Hunt, eds.), pp. 84—90. Springer-Verlag, New York.
38.
Langle, U.W., Bruggemann, S., Prentice, D.E., Ettlin, R.A., Richardson, B., Naef, R., and Cordier, A. (1993—1994). Hypertrophic osteopathy in rats following chronic administration of SDZ MNS 949, an isoquinoline. Exp Toxic Pathol45, 473—9.
39.
Larson, J.L., Pino, M.V., Geiger, L.E., and Simeone, C.R. (1996). The toxicity of repeated exposures to rolipram, a type IV phosphodiesterase inhibitor, in rats. Pharmacol Toxicol78, 44—9.
40.
Lugnier, C., and Komas, N. (1993). Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: Role in vasodilatation. Eur Heart J14(Supplement 1), 141—8.
41.
Means, J.R., Franklin, R.B., and Sandusky, G.E. (1989). Toxicological evaluation of the cardiotonic isomazole in the dog. Fundam Appl Toxicol13, 418—28.
42.
Mesfin, G.M., Piper, R.C., DuCharme, D.W., Carlson, R.G., Humphrey, S.J., and Zins, G.R. (1989). Pathogenesis of cardiovascular alterations in dogs treated with minoxidil. Tox Pathol17, 164—81.
43.
Mitsumori, K. (1990). Blood and lymphatic vessels. In Pathology of the Fischer Rat (G. Boorman, S. Eustis, M. Elwell, C. Montgomery, and W. Mackenzie , eds.), pp. 473—83. Academic Press, San Diego.
44.
Nicholson, C.D., Challiss, R.A., and Shahid, M. (1991). Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isozymes. Trends Pharmacol Sci12, 19—27.
45.
Nielson, C.P., Vestal, R.E., Sturm, R.J., and Heaslip, R. (1990). Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J Allergy Clin Immunol86, 801—8.
46.
Ottonello, L., Morone, M.P., Dapino, P., and Dallegri, F. (1995). Cyclic AMP-elevating agents down-regulate the oxidative burst induced by granulocyte-macrophage colony-stimulating factor (GM-CSF) in adherent neutrophils. Clin Exp Immunol101, 502—6.
47.
Palfreyman, M.N., and Souness, J.E. (1996). Phosphodiesterase type IV inhibitors. Prog Med Chem33, 1—52.
48.
Pino, M.V., Valerio, M.G., Miller, G.K., Larson, J.L., Rosolia, D.L., Jayyosi, Z., Crouch, C.N., Trojanowski, J.Q., and Geiger, L.E. (1999). Toxicologic and carcinogenic effects of the type IV phosphodiesterase inhibitor RP 73401 on the nasal olfactory tissue in rats . Toxicol Pathol27, 383—94.
49.
Rao, R.R., Nair, T.B., Marathe, M.R., and Gangoli, S.D. (1985). Pre-clinical toxicity studies on the new nitroimidazole 1-methylsulphonyl-3-(1-methyl-5-nitroimidazole-2-yl)-2-imidazolidinone. Arzneimittelforschung35, 1692—6.
50.
Reeves, M.L., Leigh, B.K., and England, P.J. (1987). The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Biochem J241, 535—41.
51.
Reynolds, D.J. (1995). Where do 5-HT3 receptor antagonists act as anti-emetics? In Serotonin and the Scientific Basis of Anti-emetic Therapy (D. J. Reynolds, P. L. Andrews, and C. J. Davies, eds.), pp. 111—26. Oxford Clinical Communications, Oxford.
52.
Robichaud, A., Savoie, C., Stamatiou, P.B., Tattersall, F.D., and Chan, C.C. (2001). PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway. Neuropharmacol40, 262—9.
53.
Robichaud, A., Tattersall, F.D., Choudhury, I., and Rodger, I.W. (1999). Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret. Neuropharmacol38, 289—97.
54.
Robicsek, S.A., Blanchard, D.K., Djeu, J.Y., Krzanowski, J.J., Szentivanyi, A., and Polson, J.B. (1991). Multiple high-affinity cAMP-phosphodiesterases in human T-lymphocytes. Biochem Pharmacol42, 869—77.
55.
Ruben, Z., Deslex, P., Nash, G., Redmond, N.I., Poncet, M., and Dodd, D.C. (1989). Spontaneous disseminated panarteritis in laboratory beagle dogs in a toxicity study: A possible genetic predilection. Toxicol Pathol17, 145—52.
56.
Sandusky, G.E., Means, J.R., and Yeager, H.K. (1993). Coronary artery toxicity in beagle dogs given indolidan, a type III phosphodiesterase inhibitor. Fundam Appl Toxicol21, 228—35.
57.
Sandusky, G.E., Vodicnik, M.J., and Tamura, R.N. (1991). Cardiovascular and adrenal proliferative lesions in Fischer 344 rats induced by long-term treatment with type III phosphodiesterase inhibitors (positive inotropic agents), isomazole and indolidan. Fundam Appl Toxicol16, 198—209.
58.
Schudt, C., Winder, S., Forderkunz, S., Hatzelmann, A., and Ullrich, V. (1991). Influence of selective phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Ca. Naunyn-Schmiedeberg's Arch Pharmacol344, 682—90.
59.
Slim, R.M., Song, Y., Albassam, M., and Dethloff, L.A. (2003). Apoptosis and nitrative stress associated with phosphodiesterase inhibitor-induced mesenteric vasculitis in rats. Toxicol Pathol31, 638—45.
60.
Sneller, M.C. (2002). Vasculitis secondary to bacterial, fungal, and parasitic infection. In Inflammatory Diseases of Blood Vessels (G. S. Hoffman and C. M. Weyand, eds.), pp. 599-608. Marcel Dekker, Inc., New York.
61.
Spina, D. (2000). The potential of PDE4 inhibitors in asthma or COPD. Current Opin Invest Drugs1, 204—13.
62.
Srivastava, R. (1989). Inhibition of neutrophil response by curcumin . Agents Actions28, 298—303.
63.
Torphy, T.J. (1998). Phosphodiesterase enzymes Molecular targets for novel antiasthma agents. Am J Resp Crit Care Med157, 351—70.
64.
Vogel, B., Kolopp, M., de Brugerolle de Fraissinette, A., Singer, T., Ettlin , R.A., Birnbaum, I., and Cordier, A. (1999). Minipigs in safety assessment of a phosphodiesterase type IV inhibitor for the treatment of inflammatory skin diseases. Toxicologist48(1-S), 323.
65.
Wachtel, H. (1982). Characteristic behavioral alterations in rats induced by rolipram and other selective adenosine cyclic 3',5'-monophosphate phosphodiesterase inhibitors. Psychopharmacology77, 309—16.
66.
Westwood, F.R., Iswaran, T.J., and Greaves, P. (1990). Pathologic changes in blood vessels following administration of an inotropic vasodilator (ICI 153,110) to the rat. Fundam Appl Tox14, 797—809.
67.
Westwood, F.R., Iswaran, T.J., and Greaves, P. (1991). Long-term effects of an inotropic phosphodiesterase inhibitor (ICI 153,110) on the rat salivary gland, harderian gland, and intestinal mucosaToxicol Pathol19, 214—23.
68.
Yoshino, N., Ami, Y., Terao, K., Tashiro, F., and Honda. M. (2000). Upgrading of flow cytometric analysis for absolute counts, cytokines and other antigenic molecules of cynomolgus monkeys (Macaca fascicularis) by using antihuman cross-reactive antibodies. Exp Anim49, 97—110.
69.
Zhang, J., Herman, E.H., Knapton, A., Chadwick, D.P., Whitehurst, V.E., Koerner, J.E., Papoian, T., Ferrans, V.J., and Sistare, F.D. (2002). SK&F 95654-induced acute cardiovascular toxicity in Sprague—Dawley rats— histopathologic, electron microscopic, and immunohistochemical studies. Toxicol Pathol30, 28—40.
